2 FTSE 100 giants primed to outperform the index in the long term

These two high quality stocks can continue to trounce the cyclical FTSE 100 (INDEXFTSE: UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Unilever sign

Image: Unilever. Fair use.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s never a sure thing to say any given stock will outperform its index but given the top heavy nature of the FTSE 100, skewed as it is to highly cyclical commodities producers and banks, I’m quite comfortable saying Unilever (LSE: ULVR) is likely to safely beat the index over the long run.

The main reason for this is Unilever’s much lauded defensive nature. Selling everything from Dove soaps to Lipton tea and Surf detergent provides significant downside protection as consumers largely buy these brands throughout the economic cycle.

A further dose of long term protection comes in the form of the company’s truly global reach. This keeps it from relying too much on a single market and also provides very good growth prospects as it moves into developing markets at a rapid clip.

Indeed, developing markets now account for 59% of group sales as of the end of Q1. Although many of the larger developing countries have encountered rough macroeconomic environments in recent quarters due to low commodity prices, Unilever’s sales in these countries are sailing ahead strongly. In Q1 total sales from developing markets grew 6.1% year-on-year due to both price and volume increases, showing Unilever’s vaunted non-cyclical nature and its premium pricing power.

Growth in developing markets more than made up for weak trading in developed countries and helped lead total turnover up 2.4% year-on-year in the quarter on a constant currency basis and 6.1% at actual exchange rates.

There was further good news in the quarter as the company pushed ahead with strategic changes announced after it fended off the £115bn takeover offer from KraftHeinz. These included a 12% increase to dividends and a renewed focus on margins that led management to up its guidance for operating margin improvement during the year to at least 80 basis points.

With its non-cyclical nature, exposure to high growth markets and intention to improve profitability I reckon Unilever is one great share to own for the long term.

A blockbuster in the making?

I’m equally impressed with the long term index-beating potential of GlaxoSmithKline (LSE: GSK). The drug maker’s share price has languished in recent years as investors questioned the diversification strategy of former CEO Andrew Witty but I believe the benefits of his plan are finally beginning to bear fruit.

In Q1 the group’s sales rose 5% year-on-year in constant currency terms as each of the companies major divisions, pharma, vaccines and consumer healthcare, all reported positive sales growth. What was even more impressive is that overall growth was spearheaded by 16% growth from the vaccines division, which was supposed to be a relatively slow grower.

Aside from better-than-expected growth, the vaccines and consumer healthcare division also offer non-cyclical sales that should cushion the feast or famine nature of the pharmaceutical industry. This is already the case as slow growth from the pharma division due to blockbuster drugs rolling off patent is being supplemented by reliable and growing sales from the other two.

And now that new drugs are entering the market the company looks set for a period of rapid growth. New drug sales rose 52% in Q1 and as they win approval in new markets I fully expect them and reliable sales from the other two divisions to propel GSK’s stock above and beyond the FTSE 100.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »